All In Biotech

BLA 125084 · Imclone

Erbitux

Cetuximab · Intravenous · Epidermal Growth Factor Receptor Antagonist

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Feb 12, 2004

Approved uses

9

Original approval plus efficacy supplements

Registered trials

1,124

144 Phase 3, 158 recruiting

FAERS reports

31,703

27,066 serious, 4,267 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST Infusion Reactions: ERBITUX can cause serious and fatal infusion reactions [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions [see Dosage and Administration ( 2.5 )] . Cardiopulmonary Arrest: Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration [see Warnings and Precautions ( 5.2 , 5.6 )] . WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST See full prescribing information for complete boxed warning. ERBITUX can cause serious and fatal infusion...

What it is approved for

From the label in effect Apr 16, 2026.

ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) 1.1 Squamous Cell Carcinoma of the Head and Neck (SCCHN) ERBITUX ® is indicated: in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN). in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN. as a...

Mechanism: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR, HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle. Expression of EGFR is also detected in many human cancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ERBITUX · CETUXIMAB 100mg/VIAL · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetuximab" as an intervention, any sponsor and status, largest first.

All 1,124 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash2,287
  • diarrhoea2,049
  • off label use1,923
  • nausea1,677
  • vomiting1,415
  • dyspnoea1,411
  • neutropenia1,243
  • pyrexia1,137
  • malignant neoplasm progression1,136
  • infusion related reaction1,113
  • dehydration1,106
  • fatigue1,096

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004691
20051,076
20061,313
20071,079
20081,212
20091,407
20101,576
20111,639
20121,656
20131,541
20141,570
20151,412
20161,537
20171,913
20181,472
20191,437
20201,152
20211,237
20221,283
20231,385
20241,371
20251,471
20261,273

Recalls

1 FDA enforcement reports for this application.

  • Nov 8, 2018 · Class III · Terminated

    Labeling: Missing label; potential for missing primary container label on the vial.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Erbitux (Cetuximab)

2024 spending

$6.7M

Beneficiaries

125

684 claims

Per beneficiary

$53,480

$15.40 per unit

View as table
YearSpending
2020$4,866,226
2021$4,928,471
2022$6,811,781
2023$6,921,103
2024$6,684,951

Part B: Erbitux (Cetuximab) · HCPCS J9055

2024 spending

$158M

Beneficiaries

3,387

28,555 claims

Per beneficiary

$46,542

2024 ASP limit $74.58 per unit

View as table
YearSpending
2020$144,722,196
2021$138,532,658
2022$153,951,939
2023$155,924,993
2024$157,636,301

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,389 on PubMed

Sponsor: Imclone

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.